High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin - PubMed
Review
. 2001 Jun;44(6):1010-24.
doi: 10.1067/mjd.2001.112325.
Affiliations
- PMID: 11369915
- DOI: 10.1067/mjd.2001.112325
Review
High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin
A Rütter et al. J Am Acad Dermatol. 2001 Jun.
Abstract
Adjuvant high-dose intravenous immunoglobulins (IVIgs) are being used increasingly in a range of immune-mediated and autoimmune diseases. Although numerous immunomodulatory mechanisms have been suggested, the exact mechanisms of action are poorly understood. The efficacy of IVIg in certain diseases has been proven in clinical trials, insofar as IVIg is approved as the therapy of choice for Kawasaki syndrome or idiopathic thrombocytopenic purpura. IVIg treatment has been shown to be safe, without the many drug-related adverse effects, including systemic immunosuppression, that are related to corticosteroids and other immunosuppressive agents. Current dermatologic uses of IVIg are increasing, which calls for adequately controlled clinical trials. This review focuses on experiences with IVIg therapy for skin diseases and discusses current opinion concerning its potential immunomodulating mechanisms.
Similar articles
-
Intravenous immunoglobulin: an emerging treatment for immune-mediated skin diseases.
Rütter A, Luger TA. Rütter A, et al. Curr Opin Investig Drugs. 2002 May;3(5):713-9. Curr Opin Investig Drugs. 2002. PMID: 12090544 Review.
-
Gürcan HM, Ahmed AR. Gürcan HM, et al. Ann Pharmacother. 2007 May;41(5):812-23. doi: 10.1345/aph.1K037. Epub 2007 Apr 17. Ann Pharmacother. 2007. PMID: 17440006 Review.
-
Sibéril S, Elluru S, Negi VS, Ephrem A, Misra N, Delignat S, Bayary J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Sibéril S, et al. Transfus Apher Sci. 2007 Aug;37(1):103-7. doi: 10.1016/j.transci.2007.01.012. Epub 2007 Aug 31. Transfus Apher Sci. 2007. PMID: 17765663 Review.
-
Intravenous immunoglobulin and autoimmune disease.
El-Shanawany T, Jolles S. El-Shanawany T, et al. Ann N Y Acad Sci. 2007 Sep;1110:507-15. doi: 10.1196/annals.1423.054. Ann N Y Acad Sci. 2007. PMID: 17911466
-
Intravenous immunoglobulins in the therapy of autoimmune and systemic inflammatory disorders.
Mobini N, Sarela A, Ahmed AR. Mobini N, et al. Ann Allergy Asthma Immunol. 1995 Feb;74(2):119-28; quiz 128-33. Ann Allergy Asthma Immunol. 1995. PMID: 7697470 Review.
Cited by
-
Mechanisms of Obesity-Induced Changes in Pharmacokinetics of IgG in Rats.
Gao X, Sheng YH, Yu S, Li J, Rosa R, Girgis S, Guo T, Brunetti L, Kagan L. Gao X, et al. Pharm Res. 2023 May;40(5):1223-1238. doi: 10.1007/s11095-023-03496-y. Epub 2023 Mar 22. Pharm Res. 2023. PMID: 36949370 Free PMC article.
-
Chronic urticaria and treatment options.
Godse KV. Godse KV. Indian J Dermatol. 2009;54(4):310-2. doi: 10.4103/0019-5154.57603. Indian J Dermatol. 2009. PMID: 20101328 Free PMC article.
-
Beausang JF, Fan HC, Sit R, Hutchins MU, Jirage K, Curtis R, Hutchins E, Quake SR, Yabu JM. Beausang JF, et al. J Transl Med. 2017 Jan 13;15(1):9. doi: 10.1186/s12967-017-1118-7. J Transl Med. 2017. PMID: 28086979 Free PMC article. Clinical Trial.
-
Baek DW, Song GY, Lee HS, Do YR, Lee JH, Yhim HY, Moon JH, Yang DH. Baek DW, et al. Front Oncol. 2024 Apr 23;14:1380492. doi: 10.3389/fonc.2024.1380492. eCollection 2024. Front Oncol. 2024. PMID: 38715775 Free PMC article.
-
Pharmacokinetic modeling of therapies for systemic lupus erythematosus.
Yang X, Sherwin CM, Yu T, Yellepeddi VK, Brunner HI, Vinks AA. Yang X, et al. Expert Rev Clin Pharmacol. 2015;8(5):587-603. doi: 10.1586/17512433.2015.1059751. Epub 2015 Jul 9. Expert Rev Clin Pharmacol. 2015. PMID: 26143647 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical